ClinicalTrials.gg
CompletedNCT00516802Updated May 15, 2009

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

A Phase 1 interventional study of KU-0059436 (AZD2281)(PARP inhibitor) and dacarbazine in Melanoma Neoplasms, sponsored by AstraZeneca. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-05-15.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies testing dacarbazine in Melanoma — none open to participants now, 1 under way, none of them phase 3. Dacarbazine · Melanoma.

Enrollment
16th of 25
40 · median 64
Started
2007
with 4 others
Phase 1
4 of 30
none open now
Registered
14th of 30
by date
Lead sponsor
1 of 30
AstraZeneca

Among the 30 studies testing dacarbazine in Melanoma, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2007, is one of 4 in phase 1, and was the 14th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 30 studies testing dacarbazine in Melanoma is open now. The open studies under Melanoma, anywhere →

About dacarbazine

Dacarbazine: first FDA approval 1975 (DTIC-DOME). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing dacarbazine in Melanoma as a file.
02

Study summary

This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic chemotherapy.

03

Conditions studied

  • Melanoma Neoplasms

Browse trials for

Keywords

  • Poly(ADP ribose) polymerases
  • dacarbazine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have:

    1. Unresectable stage 3 or stage 4 cutaneous melanoma or unknown primary melanoma with .
    2. Histological or cytological confirmation of melanoma. Histological confirmation of melanoma from the primary site will suffice, unless the primary site is unknown.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with cytotoxic chemotherapy for advanced melanoma, apart from treatment for melanoma with isolated limb perfusion.
  • Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or use of other agents within 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used).
  • Major surgery within 4 weeks of starting the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    1

    DTIC + KU-0059436

    Drug: KU-0059436 (AZD2281)(PARP inhibitor) · Drug: dacarbazine

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the safety, tolerability, dose-limiting toxicity (DLT), and (MTD) of KU-0059436 in combination with dacarbazine.

    Time frame: assessed every 3 weeks

Secondary outcomes

  1. Objective tumour response

    Time frame: assessed every 6 weeks

07

Study locations

4 sites
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    London, United Kingdom
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Oxford, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2007
First posted
Aug 15, 2007
Start
Jan 2007
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Last update
May 15, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00516802
Lead sponsor
AstraZeneca
Collaborators
KuDOS Pharmaceuticals Limited
First posted
Aug 15, 2007
Start date
Jan 2007
Primary completion
Jan 2009
Completion
Jan 2009
Last update
May 15, 2009

Study contacts

Prof James Carmichael, BSc MBChB MD FRCP
study director · KuDOS Pharmaceuticals Ltd
Prof Martin Gore, PhD MRCP FRCR
principal investigator · Royal Marsden Hospital Trust, London, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Dacarbazine

Start the discussion